Alzheimer's failure spawns 130 job cuts at J&J

Tools

A doomed Alzheimer's program has triggered layoffs. Johnson & Johnson ($JNJ) is making deep cuts in an Alzheimer's immunotherapy unit in the aftermath of a colossal Phase III failure of a program to advance bapineuzumab against the memory-stealing disease. Report